Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIUMVI vs ANTHIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
FDA: Treatment of chronic lymphocytic leukemia (CLL) (not approved; withdrawn from market),Off-label: None
BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
Terminal elimination half-life is approximately 19-20 days (range 11-30 days) in patients with relapsing multiple sclerosis. The long half-life supports every-6-month dosing.
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Ublituximab is a monoclonal antibody catabolized into small peptides and amino acids via general protein degradation pathways; no specific metabolic enzymes are involved.
Metabolized by exonucleases to shorter oligonucleotides.
BRIUMVI (ublituximab) is a monoclonal antibody. Elimination occurs via intracellular catabolism and is not excreted renally or fecally in significant amounts. No specific excretion data available.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Not extensively bound to plasma proteins (expected low binding for monoclonal antibodies); specific % not reported.
Approximately 57% bound to plasma proteins (including albumin and immunoglobulins)
Approximately 3.5 L (not weight-based; ~0.05 L/kg for a 70 kg patient). Small Vd consistent with limited extravascular distribution of monoclonal antibodies.
Volume of distribution: approximately 0.16–0.20 L/kg; indicates limited extravascular distribution, consistent with a monoclonal antibody
100% (intravenous administration only; not administered via other routes).
Intravenous: 100% bioavailability; no other routes are approved or clinically relevant
No dose adjustment is recommended for patients with mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C).
Safety and effectiveness in pediatric patients (age <18 years) have not been established. No recommended dosing.
For patients weighing 10 kg to <40 kg: 14 mg/kg IV (max 800 mg) over 90 minutes, then 7 mg/kg IV (max 400 mg) over 90 minutes at 2 and 4 weeks post-first dose. For patients ≥40 kg: same as adult dosing.
No specific dose adjustment is recommended. Clinical studies did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.
No specific dose adjustment recommended; clinical studies did not include sufficient numbers of patients aged ≥65 years to determine whether they respond differently. Use with caution.
None
None.
Infusion reactions (may require premedication and monitoring),Increased risk of infections (including serious and life-threatening infections),Progressive multifocal leukoencephalopathy (PML) in patients treated with anti-CD20 therapies,Hepatitis B reactivation (perform HBV screening before initiation),Immunoglobulin levels reduction requiring monitoring,Increased risk of malignancies (breast cancer observed in clinical trials)
Myelosuppression,Infusion reactions,Tumor lysis syndrome,Electrolyte abnormalities,Cardiotoxicity
Active hepatitis B infection,Severe, active infections (until resolved)
Hypersensitivity to oblimersen or any component of the formulation
No known food interactions. Grapefruit and other CYP450 modulators are not expected to affect ublituximab as it is a monoclonal antibody cleared via catabolism.
No known food interactions. ANTHIM is administered intravenously, and food intake does not affect its pharmacokinetics.
BRIUMVI (ublituximab) is a monoclonal antibody, and Ig G antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimester. Based on its mechanism of action (CD20-mediated B-cell depletion), there is a potential risk of transient peripheral B-cell depletion in the fetus. Animal studies have not been conducted with ublituximab; however, other anti-CD20 antibodies have shown no teratogenicity but can cause neonatal B-cell depletion. The drug should be avoided during pregnancy unless the benefit justifies the potential risk.
ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data is limited. As a Ig G1 monoclonal antibody, it is expected to cross the placenta increasingly after the first trimester. The risk is likely low but cannot be excluded. Use only if clearly needed.
It is unknown whether ublituximab is excreted in human milk. Monoclonal antibodies are generally present in breast milk in low amounts, but absorption by the infant is limited due to gastrointestinal degradation. Since ublituximab can cause B-cell depletion, a risk to the breastfed infant cannot be excluded. The M/P ratio is not known.
It is not known whether obiltoxaximab is excreted in human milk. Monoclonal antibodies are typically excreted in breast milk at low levels with limited oral bioavailability due to gastrointestinal degradation. The M/P ratio is unknown. Caution should be exercised, but benefits of breastfeeding and maternal therapy should be considered.
No specific dose adjustments are recommended during pregnancy due to lack of pharmacokinetic data. However, pregnancy can alter clearance and volume of distribution for monoclonal antibodies, potentially affecting exposure. Current guidelines do not specify dose modifications for ublituximab in pregnancy; clinical judgment is advised.
No dose adjustment is required for ANTHIM based on pregnancy. Pharmacokinetic studies in pregnant women are not available; however, pregnancy-related changes in volume of distribution and renal clearance may alter drug levels, but clinical significance is unknown. Standard adult dosing is recommended.
Premedicate with corticosteroids, antihistamines, and acetaminophen to reduce infusion reactions. Monitor for hypersensitivity reactions, especially during first infusion. Screen for hepatitis B and tuberculosis before initiation. Avoid live vaccines during treatment. Consider JCV antibody status due to risk of progressive multifocal leukoencephalopathy (PML) with anti-CD20 therapies.
ANTHIM (obiltoxaximab) is a monoclonal antibody indicated for inhalational anthrax. It should be administered as soon as possible after suspected or confirmed exposure. Premedication with diphenhydramine may reduce infusion reactions. Monitor for anaphylaxis and infusion-related reactions. Efficacy is established in animal models due to ethical limitations.
You must take premedications before each infusion to lower the risk of allergic reactions.,Report any symptoms like fever, chills, rash, or difficulty breathing during or after infusion.,Inform your doctor if you have a history of hepatitis B, tuberculosis, or any infections.,Do not receive live vaccines while on this medication and for a period after stopping.,This drug may increase your risk of infections; contact your doctor if you develop signs of infection.,You will need regular blood tests to monitor for side effects.
ANTHIM is used to treat or prevent inhalational anthrax, which can be fatal if not treated.,You will receive this medication as an intravenous (IV) infusion over 1.5 hours.,You may experience side effects such as pain or swelling at the infusion site, headache, itching, or feeling tired.,Serious allergic reactions can occur; tell your healthcare provider immediately if you develop rash, hives, difficulty breathing, or swelling of the face or throat.,Because ANTHIM is made from mouse proteins, it can cause allergic reactions in some people.,This medication should not replace a recommended vaccination program for anthrax.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIUMVI vs ANTHIM, answered by our medical review team.
BRIUMVI is a Monoclonal Antibody that works by BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.. ANTHIM is a Monoclonal Antibody that works by Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIUMVI and ANTHIM depend on the specific clinical indication. These are both Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIUMVI is: BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.. The standard adult dose of ANTHIM is: 800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIUMVI and ANTHIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIUMVI is classified as Category C. BRIUMVI (ublituximab) is a monoclonal antibody, and IgG antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimes. ANTHIM is classified as Category C. ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.